CFA
SPRO icon

Carroll Financial Associates’s Spero Therapeutics SPRO Stock Holding History

Carroll Financial Associates’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$1K Hold
110
– – ﹤0.01% 1579
2021
Q3 		$2K Hold
110
– – ﹤0.01% 1574
2021
Q2 		$1K Hold
110
– – ﹤0.01% 1651
2021
Q1 		$1K Buy
+110
New +$1.94K ﹤0.01% 1592

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Carroll Financial Associates's SPRO Position: Q4 2021 in Review

Carroll Financial Associates held its Spero Therapeutics (SPRO) position steady in Q4 2021 at 110 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1579.

Carroll Financial Associates first reported a position in SPRO in Q1 2021 and has held it in 4 quarters since. The position peaked at $2K in Q3 2021. 84 funds tracked by Wall St. Rank hold SPRO as of Q4 2021.

  • Carroll Financial Associates held 110 shares of Spero Therapeutics worth $1K as of Q4 2021.
  • Carroll Financial Associates left its Spero Therapeutics share count unchanged in Q4 2021.
  • Spero Therapeutics made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1579 holding.
  • Carroll Financial Associates first reported a position in Spero Therapeutics in Q1 2021 and has held it in 4 quarters since.
  • Carroll Financial Associates's Spero Therapeutics position peaked at $2K in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.